CD14 and rheumatoid arthritis: The present data show that the absolute number of circulating monocytes, and the numbers of CD14+highCD16−, CD14+highCD16+ and CD14+lowCD16+ subset cells, are strongly predictive of the clinical response of naive patients with RA to MTX treatment.